Page last updated: 2024-11-05

thalidomide and Prurigo

thalidomide has been researched along with Prurigo in 60 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Prurigo: A name applied to several itchy skin eruptions of unknown cause. The characteristic course is the formation of a dome-shaped papule with a small transient vesicle on top, followed by crusting over or lichenification. (From Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment."9.11Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004)
"Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age."9.08Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. ( Bielsa, I; Carrascosa, JM; Ferrándiz, C; Just, M; Ribera, M, 1997)
"Thalidomide has been used as an effective treatment for prurigo nodularis (PN) with a median dose of 200 mg, but the risk of peripheral neuropathy precludes long-term use."7.96An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis. ( Gupta, A; Sardana, K; Sinha, S, 2020)
"The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects."7.77Thalidomide in 42 patients with prurigo nodularis Hyde. ( Andersen, TP; Fogh, K, 2011)
"Actinic prurigo patients were analyzed before and after thalidomide treatment."7.72Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. ( Cortés-Franco, R; Domínguez-Soto, L; Estrada-G, I; Estrada-Parra, S; Flores-Romo, L; Garibay-Escobar, A; Hojyo-Tomoka, T; Núñez-Vázquez, A; Pérez-Uribe, A; Santos-Argumedo, L; Vega-Memije, E, 2004)
"Twenty-two patients suffering from prurigo nodularis were treated with thalidomide 50-300 mg daily for an average of 12 months (two weeks to five years), following a special arrangement between the Danish Government and the producer Grünenthal GMBH, by which the Government took full economical responsibility for any claims related to the treatment."7.68[Thalidomide treatment of prurigo nodularis]. ( Jøhnke, H; Zachariae, H, 1993)
"Four patients with classic recalcitrant prurigo nodularis had symptomatic and physical responses to thalidomide with remissions."7.67Thalidomide treatment of prurigo nodularis. ( Connolly, SM; Doyle, JA; Padilha-Goncalves, A; Winkelmann, RK, 1984)
"A 57-year-old man with prurigo nodularis, was unresponsive to conventional therapy, was successfully treated with thalidomide."7.66Treatment of prurigo nodularis with thalidomide. ( van den Broek, H, 1980)
"The concentration of iron, cooper and zinc in the skin of patients with prurigo nodularis was measured by diagnostic X-ray spectrometry before and after treatment with thalidomide."7.66In vivo measurements of iron, copper and zinc in the skin of prurigo nodularis patients treated with thalidomide. ( Gorodetzky, R; Loewinger, E; Sheskin, J; Weinreb, A, 1981)
"The literature concerning the use and possible mode of action of thalidomide in reactional lepromatous leprosy and in various other conditions is reviewed."7.66Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. ( Barnhill, RL; McDougall, AC, 1982)
"Fourteen patients suffering from actinic prurigo were treated with thalidomide."7.66Thalidomide in actinic prurigo. ( Calnan, CD; Hawk, JL; Lovell, CR; Magnus, IA, 1983)
"In the past, the regimen for treatment of prurigo nodularis often required thalidomide at 200 mg/day."6.73Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. ( Chai, CY; Chen, GS; Chen, WT; Lan, CC; Lin, CL; Wu, CS, 2007)
"Actinic prurigo is an uncommon and usually persistent idiopathic photodermatosis with typical human leukocyte antigen (HLA) associations (HLA-DR4, particularly subtypes DRB1*0407 and DRB1*0401)."6.41A case of severe actinic prurigo successfully treated with thalidomide. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2001)
"Thalidomide is an antipruritic and anti-inflammatory agent that has shown to be very effective in treating a variety of dermatologic conditions."5.48Thalidomide for the treatment of chronic refractory prurigo nodularis. ( Aguh, C; He, A; Kwatra, SG; Okoye, GA, 2018)
"Thalidomide is an effective treatment option in cases of recalcitrant PN; however, its most frequent adverse effect is neurotoxicity, which often results in its discontinuation."5.46Treatment of prurigo nodularis with lenalidomide. ( Arjona-Aguilera, C; Jiménez-Gallo, D; Linares-Barrios, M; Ossorio-García, L; Rodríguez-Mateos, ME, 2017)
"Actinic prurigo is a rare, often difficult-to-treat, idiopathic photodermatosis."5.33Successful thalidomide therapy for actinic prurigo in a European woman. ( Hofer, A; Holzer, A; Kerl, H; Legat, FJ; Wolf, P, 2006)
" This case illustrates the safe long-term use of thalidomide."5.31Long-term thalidomide for actinic prurigo. ( Muir, JB; Yong-Gee, SA, 2001)
"The US FDA-approved thalidomide for the treatment of chronic recurrent/severe erythema nodosum leprosum."5.12Thalidomide: an experience in therapeutic outcome and adverse reactions. ( Gupta, M; Mahajan, VK; Ranjan, N; Shanker, V; Sharma, NL; Sharma, VC, 2007)
"To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment."5.11Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004)
"Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age."5.08Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. ( Bielsa, I; Carrascosa, JM; Ferrándiz, C; Just, M; Ribera, M, 1997)
"The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects."3.77Thalidomide in 42 patients with prurigo nodularis Hyde. ( Andersen, TP; Fogh, K, 2011)
"Actinic prurigo patients were analyzed before and after thalidomide treatment."3.72Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. ( Cortés-Franco, R; Domínguez-Soto, L; Estrada-G, I; Estrada-Parra, S; Flores-Romo, L; Garibay-Escobar, A; Hojyo-Tomoka, T; Núñez-Vázquez, A; Pérez-Uribe, A; Santos-Argumedo, L; Vega-Memije, E, 2004)
"St Vincent's Hospital Melbourne cautiously prescribes thalidomide as a treatment for recalcitrant dermatoses."3.71Thalidomide experience of a major Australian teaching hospital. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2002)
"We report a case of toxic pustuloderma secondary to thalidomide in a patient with severe nodular prurigo."3.69Thalidomide-induced toxic pustuloderma. ( Basarab, T; Darvay, A; Russell-Jones, R, 1997)
"Twenty-two patients suffering from prurigo nodularis were treated with thalidomide 50-300 mg daily for an average of 12 months (two weeks to five years), following a special arrangement between the Danish Government and the producer Grünenthal GMBH, by which the Government took full economical responsibility for any claims related to the treatment."3.68[Thalidomide treatment of prurigo nodularis]. ( Jøhnke, H; Zachariae, H, 1993)
"Seven patients with prurigo nodularis and one with aphthous stomatitis were given 40-115 g of thalidomide for 1 to 6 years."3.67Development of polyneuropathy during thalidomide therapy. ( Asboe-Hansen, G; Brodthagen, H; Høyer, H; Wulff, CH, 1985)
"Of six patients treated with thalidomide for either prurigo nodularis or discoid lupus erythematosus, four had paresthesias in the hands and feet and one also complained of muscular pain and stiffness."3.67Thalidomide neurotoxicity. ( Andersen, KE; Clemmensen, OJ; Olsen, PZ, 1984)
"Sensory neuropathies developed in three of four patients with prurigo nodularis who had been treated with thalidomide."3.67Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. ( Antel, J; Aronson, IK; Van den Broek, H; West, DP; Yu, R, 1984)
"Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug."3.66[Thalidomide in dermatology]. ( Hunziker, T; Krebs, A, 1983)
"The literature concerning the use and possible mode of action of thalidomide in reactional lepromatous leprosy and in various other conditions is reviewed."3.66Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. ( Barnhill, RL; McDougall, AC, 1982)
"Thalidomide was studied by 6 reports providing evidence of good symptom response, only 2 of which were rated level 2b or greater."2.61A systematic review of evidence-based treatments for prurigo nodularis. ( Abate, LE; Friedman, AJ; Qureshi, AA; Yosipovitch, G, 2019)
"Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects."2.43Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005)
"Actinic prurigo is an uncommon and usually persistent idiopathic photodermatosis with typical human leukocyte antigen (HLA) associations (HLA-DR4, particularly subtypes DRB1*0407 and DRB1*0401)."2.41A case of severe actinic prurigo successfully treated with thalidomide. ( Baker, CS; Crouch, RB; Foley, PA; Ng, JC, 2001)
"Thalidomide is an antipruritic and anti-inflammatory agent that has shown to be very effective in treating a variety of dermatologic conditions."1.48Thalidomide for the treatment of chronic refractory prurigo nodularis. ( Aguh, C; He, A; Kwatra, SG; Okoye, GA, 2018)
"Thalidomide is an effective treatment option in cases of recalcitrant PN; however, its most frequent adverse effect is neurotoxicity, which often results in its discontinuation."1.46Treatment of prurigo nodularis with lenalidomide. ( Arjona-Aguilera, C; Jiménez-Gallo, D; Linares-Barrios, M; Ossorio-García, L; Rodríguez-Mateos, ME, 2017)
"Nodular prurigo is characterized by nodules and papules that are intensely pruritic."1.34Peripheral neuropathy associated with nodular prurigo. ( Bharati, A; Wilson, NJ, 2007)
"Actinic prurigo is a rare, often difficult-to-treat, idiopathic photodermatosis."1.33Successful thalidomide therapy for actinic prurigo in a European woman. ( Hofer, A; Holzer, A; Kerl, H; Legat, FJ; Wolf, P, 2006)
"Actinic prurigo is a specific familial photodermatosis of uncertain pathogenesis."1.31Effectors of inflammation in actinic prurigo. ( Arrese, JE; Cortés-Franco, R; Dominguez-Soto, L; Guevara, E; Hojyo-Tomoka, MT; Piérard, GE; Vega-Memije, E, 2001)
" This case illustrates the safe long-term use of thalidomide."1.31Long-term thalidomide for actinic prurigo. ( Muir, JB; Yong-Gee, SA, 2001)

Research

Studies (60)

TimeframeStudies, this research(%)All Research%
pre-199015 (25.00)18.7374
1990's13 (21.67)18.2507
2000's19 (31.67)29.6817
2010's8 (13.33)24.3611
2020's5 (8.33)2.80

Authors

AuthorsStudies
Frølunde, AS1
Wiis, MAK1
Ben Abdallah, H1
Elsgaard, S1
Danielsen, AK1
Deleuran, M1
Vestergaard, C1
Liu, T1
Chu, Y1
Li, S1
Fang, H1
Qiao, J1
Todberg, T1
Skov, L1
Simonsen, S1
Kainu, K1
Zachariae, C1
Arasu, A1
Lee, S1
Chian Yeoh, A1
Ross, G1
Aguh, C1
Kwatra, SG1
He, A1
Okoye, GA1
Qureshi, AA1
Abate, LE1
Yosipovitch, G1
Friedman, AJ1
Sardana, K1
Gupta, A1
Sinha, S1
Liu, H1
Gaspari, AA1
Schleichert, R1
Rishi, R1
Ringwala, S1
Tracy, J1
Fatteh, S1
Ossorio-García, L1
Jiménez-Gallo, D1
Rodríguez-Mateos, ME1
Arjona-Aguilera, C1
Linares-Barrios, M1
Taefehnorooz, H1
Truchetet, F1
Barbaud, A1
Schmutz, JL1
Bursztejn, AC1
Andersen, TP1
Fogh, K1
Kanavy, H1
Bahner, J1
Korman, NJ1
Vega-Memije, ME2
Mosqueda-Taylor, A1
Irigoyen-Camacho, ME1
Hojyo-Tomoka, MT3
Domínguez-Soto, L4
Crouch, RB2
Foley, PA2
Ng, JC2
Baker, CS2
Giannini, F1
Volpi, N1
Rossi, S1
Passero, S1
Fimiani, M1
Cerase, A1
Alfadley, A1
Al-Hawsawi, K1
Thestrup-Pedersen, K1
Al-Aboud, K1
Cortes-Franco, R3
Maurer, T1
Poncelet, A1
Berger, T1
Estrada-G, I1
Garibay-Escobar, A1
Núñez-Vázquez, A1
Hojyo-Tomoka, T1
Vega-Memije, E2
Pérez-Uribe, A1
Flores-Romo, L1
Santos-Argumedo, L1
Estrada-Parra, S1
Ozanic Bulic, S1
Fassihi, H1
Mellerio, JE1
McGrath, JA1
Atherton, DJ1
Wu, JJ1
Huang, DB1
Pang, KR1
Hsu, S1
Tyring, SK1
Lee, MR1
Shumack, S1
Bharati, A1
Wilson, NJ1
Holzer, A1
Wolf, P1
Legat, FJ1
Kerl, H1
Hofer, A1
Lan, CC1
Lin, CL1
Wu, CS1
Chai, CY1
Chen, WT1
Chen, GS1
Sharma, NL1
Sharma, VC1
Mahajan, VK1
Shanker, V1
Ranjan, N1
Gupta, M1
Stockbridge, EB1
Deleuran, MS1
Steiniche, T1
Aronson, IK1
Yu, R1
West, DP1
Van den Broek, H2
Antel, J1
Grosshans, E1
Illy, G1
Winkelmann, RK1
Connolly, SM1
Doyle, JA1
Padilha-Goncalves, A1
Nougué, J1
Nougué, M1
Bazex, J1
Hayek, JP1
Bidouze, H1
Høyer, H2
Wulff, CH2
Asboe-Hansen, G2
Brodthagen, H2
Clemmensen, OJ1
Olsen, PZ1
Andersen, KE1
Lovell, CR1
Hawk, JL4
Calnan, CD2
Magnus, IA1
Hunziker, T1
Krebs, A1
Barnhill, RL1
McDougall, AC1
Sheskin, J2
Gorodetzky, R1
Loewinger, E1
Weinreb, A1
Berger, TG1
Hoffman, C1
Thieberg, MD1
Judge, MR1
Kobza-Black, A1
Bielsa, I2
Teixidó, J1
Ribera, M2
Ferrándiz, C2
Jøhnke, H1
Zachariae, H1
Grabczyska, SA1
Carrascosa, JM1
Just, M1
Darvay, A1
Basarab, T1
Russell-Jones, R1
Bronner, GM1
Koks, CH1
Beijnen, JH1
Herranz, P1
Pizarro, A1
De Lucas, R1
Arribas, JR1
García-Tobaruela, A1
Peña, JM1
Casado, M1
Sadoh, DR1
Panayiotopoulos, CP1
Rao, DG1
Kane, NM1
Oware, A1
Arrese, JE1
Guevara, E1
Piérard, GE1
Yong-Gee, SA1
Muir, JB1
Meara, RH1
Carmichael, AJ1
Knight, A1
Bernal, JE1
Duran, MM1
Londoño, F1
Umaña, A1
Revuz, J1
Naafs, B1
Faber, WR1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431]Phase 493 participants (Actual)Interventional2017-06-05Completed
A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation[NCT00004635]Phase 3159 participants (Actual)Interventional2000-03-01Completed
A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer[NCT00001446]Phase 264 participants Interventional1995-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Serum Levels of Hydroxycloroquine

Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
Inactive SLE With Standard Dose of HCQ991.6
Inactive SLE With Reduced Dose of HCQ569.0

Serum Levels of Thalidomide

Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
SLE/Cutaneous Lupus With Thalidomide415.1

The Number of Participants With Adverse Events

Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00004635)
Timeframe: Date treatment consent signed to date off study, approximately 60 months

InterventionParticipants (Count of Participants)
Thalidomide117
Placebo98

Time to Progression

Time to progression is defined as follows: if the PSA returns to baseline (defined as the PSA value prior to starting leuprolide or goserelin) or increases to the absolute value of 5 ng/ml. (NCT00004635)
Timeframe: 36 months

Interventionmonths (Median)
Thalidomide15
Placebo9.6

Reviews

10 reviews available for thalidomide and Prurigo

ArticleYear
Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options.
    Dermatology (Basel, Switzerland), 2022, Volume: 238, Issue:5

    Topics: Chronic Disease; Graft vs Host Disease; Humans; Hypersensitivity, Immediate; Prurigo; Pruritus; Skin

2022
A systematic review of evidence-based treatments for prurigo nodularis.
    Journal of the American Academy of Dermatology, 2019, Volume: 80, Issue:3

    Topics: Adrenal Cortex Hormones; Anticonvulsants; Antidepressive Agents; Antipruritics; Calcineurin Inhibito

2019
Treatment of prurigo nodularis with thalidomide: a case report and review of the literature.
    International journal of dermatology, 2003, Volume: 42, Issue:5

    Topics: Adult; Dermatologic Agents; Extremities; Humans; Male; Peripheral Nervous System Diseases; Prurigo;

2003
Diagnosis and treatment of actinic prurigo.
    Dermatologic therapy, 2003, Volume: 16, Issue:1

    Topics: Dermatologic Agents; Diagnosis, Differential; Humans; Photosensitivity Disorders; Prurigo; Thalidomi

2003
Thalidomide: dermatological indications, mechanisms of action and side-effects.
    The British journal of dermatology, 2005, Volume: 153, Issue:2

    Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh

2005
Prurigo nodularis: a review.
    The Australasian journal of dermatology, 2005, Volume: 46, Issue:4

    Topics: Administration, Topical; Antipruritics; Capsaicin; Cholecalciferol; Combined Modality Therapy; Cryot

2005
Thalidomide therapy for inflammatory dermatoses.
    International journal of dermatology, 1984, Volume: 23, Issue:9

    Topics: Abnormalities, Drug-Induced; Adult; Animals; Chemical Phenomena; Chemistry; Female; Humans; Immunity

1984
Managing PLE and actinic prurigo.
    The Practitioner, 1997, Volume: 241, Issue:1571

    Topics: Acute Disease; Anti-Inflammatory Agents; Humans; Immunosuppressive Agents; Photosensitivity Disorder

1997
A case of severe actinic prurigo successfully treated with thalidomide.
    The Australasian journal of dermatology, 2001, Volume: 42, Issue:3

    Topics: Adult; Arm; Dermatitis, Photoallergic; Dermatologic Agents; Diagnosis, Differential; Facial Dermatos

2001
[Current use of thalidomide].
    Annales de dermatologie et de venereologie, 1990, Volume: 117, Issue:4

    Topics: Abnormalities, Drug-Induced; Behcet Syndrome; Dose-Response Relationship, Drug; Humans; Leprosy, Lep

1990

Trials

4 trials available for thalidomide and Prurigo

ArticleYear
Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
    Archives of dermatology, 2004, Volume: 140, Issue:7

    Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; HIV Infections; Humans; Imm

2004
Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide.
    The Journal of dermatology, 2007, Volume: 34, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Female; Humans; Immunosuppressive Agents; Male; Middle

2007
Thalidomide: an experience in therapeutic outcome and adverse reactions.
    The Journal of dermatological treatment, 2007, Volume: 18, Issue:6

    Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Erythema Nodosum; Female; Humans; Leprosy; Lichen

2007
Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis.
    Dermatology (Basel, Switzerland), 1997, Volume: 195, Issue:4

    Topics: Administration, Oral; Adult; Age Factors; Chronic Disease; Combined Modality Therapy; Female; Follow

1997

Other Studies

46 other studies available for thalidomide and Prurigo

ArticleYear
Clinical and immunological phenotype switch to prurigo nodularis in a patient receiving ixekizumab for treating psoriasis: a case report.
    International journal of dermatology, 2023, Volume: 62, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Humans; Prurigo; Psoriasis; Thalidomide

2023
Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study.
    Acta dermato-venereologica, 2020, Apr-21, Volume: 100, Issue:8

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemokines; Female; Humans; Male; Middle Aged; Pilot

2020
Drug survival of thalidomide for dermatological conditions: A single-centre review.
    The Australasian journal of dermatology, 2021, Volume: 62, Issue:1

    Topics: Dermatologic Agents; Humans; Prurigo; Skin Diseases; Stomatitis, Aphthous; Thalidomide

2021
Thalidomide for the treatment of chronic refractory prurigo nodularis.
    Dermatology online journal, 2018, Mar-15, Volume: 24, Issue:3

    Topics: Administration, Topical; Aged; Biopsy; Chronic Disease; Dose-Response Relationship, Drug; Female; Ha

2018
An observational analysis of low-dose thalidomide in recalcitrant prurigo nodularis.
    Clinical and experimental dermatology, 2020, Volume: 45, Issue:1

    Topics: Adult; Antipruritics; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Male;

2020
Use of lenalidomide in treating refractory prurigo nodularis.
    Journal of drugs in dermatology : JDD, 2013, Volume: 12, Issue:3

    Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Thalidomide; Treatment Outc

2013
Prurigo nodularis and Hashimoto thyroiditis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2014, Volume: 113, Issue:6

    Topics: Diagnosis, Differential; Female; Hashimoto Disease; Humans; Immunologic Factors; Middle Aged; Prurig

2014
Treatment of prurigo nodularis with lenalidomide.
    Dermatologic therapy, 2017, Volume: 30, Issue:2

    Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Remission Induction; Thalid

2017
Efficacy of thalidomide in the treatment of prurigo nodularis.
    Acta dermato-venereologica, 2011, Volume: 91, Issue:3

    Topics: Adult; Aged; Dermatologic Agents; Female; France; Humans; Male; Middle Aged; Prurigo; Retrospective

2011
Thalidomide in 42 patients with prurigo nodularis Hyde.
    Dermatology (Basel, Switzerland), 2011, Volume: 223, Issue:2

    Topics: Female; Humans; Immunosuppressive Agents; Male; Peripheral Nervous System Diseases; Prurigo; Retrosp

2011
Treatment of refractory prurigo nodularis with lenalidomide.
    Archives of dermatology, 2012, Volume: 148, Issue:7

    Topics: Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Prurigo; Pruritus; Thalidomide; Trea

2012
Actinic prurigo cheilitis: clinicopathologic analysis and therapeutic results in 116 cases.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 94, Issue:1

    Topics: Administration, Topical; Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anti-Inflamma

2002
Thalidomide experience of a major Australian teaching hospital.
    The Australasian journal of dermatology, 2002, Volume: 43, Issue:4

    Topics: Adolescent; Adult; Aged; Behcet Syndrome; Dermatologic Agents; Female; Humans; Lupus Erythematosus,

2002
Thalidomide-induced neuropathy: a ganglionopathy?
    Neurology, 2003, Mar-11, Volume: 60, Issue:5

    Topics: Aged; Evoked Potentials, Somatosensory; Gait Disorders, Neurologic; Ganglia, Spinal; Humans; Magneti

2003
Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo.
    International journal of dermatology, 2004, Volume: 43, Issue:12

    Topics: Adolescent; Adult; CD3 Complex; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interfe

2004
Thalidomide in the management of epidermolysis bullosa pruriginosa.
    The British journal of dermatology, 2005, Volume: 152, Issue:6

    Topics: Adolescent; Epidermolysis Bullosa Dystrophica; Female; Humans; Immunosuppressive Agents; Point Mutat

2005
Peripheral neuropathy associated with nodular prurigo.
    Clinical and experimental dermatology, 2007, Volume: 32, Issue:1

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neural Conduction; Peripheral Nervous System Disease

2007
Successful thalidomide therapy for actinic prurigo in a European woman.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2006, Volume: 4, Issue:11

    Topics: Adult; Europe; Female; Humans; Photosensitivity Disorders; Prurigo; Thalidomide; Treatment Outcome

2006
[Actinic prurigo].
    Ugeskrift for laeger, 2008, Mar-31, Volume: 170, Issue:14

    Topics: Child; Dermatologic Agents; Female; Humans; Prurigo; Thalidomide

2008
Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures.
    Archives of dermatology, 1984, Volume: 120, Issue:11

    Topics: Adult; Aged; Animals; Cells, Cultured; Female; Fetus; Ganglia, Spinal; Humans; Male; Middle Aged; Ne

1984
Thalidomide treatment of prurigo nodularis.
    Acta dermato-venereologica, 1984, Volume: 64, Issue:5

    Topics: B-Lymphocytes; Female; Humans; Immunoglobulin E; Middle Aged; Prurigo; T-Lymphocytes; Thalidomide

1984
[Occurrence of a genital hemorrhage in prurigo nodularis treated with thalidomide].
    Annales de dermatologie et de venereologie, 1983, Volume: 110, Issue:6-7

    Topics: Female; Humans; Metrorrhagia; Middle Aged; Prurigo; Thalidomide

1983
[Treatment of prurigo nodularis Hyde with thalidomide].
    Ugeskrift for laeger, 1983, Oct-17, Volume: 145, Issue:42

    Topics: Aged; Female; Humans; Male; Middle Aged; Nervous System Diseases; Prurigo; Thalidomide

1983
Thalidomide neurotoxicity.
    Archives of dermatology, 1984, Volume: 120, Issue:3

    Topics: Adult; Aged; Carpal Tunnel Syndrome; Electromyography; Female; Humans; Lupus Erythematosus, Discoid;

1984
Thalidomide in actinic prurigo.
    The British journal of dermatology, 1983, Volume: 108, Issue:4

    Topics: Adolescent; Adult; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Male; Midd

1983
[Thalidomide in dermatology].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1983, Volume: 34, Issue:2

    Topics: Animals; Female; Guinea Pigs; Humans; Immunity; Leprosy; Lupus Erythematosus, Discoid; Male; Mice; N

1983
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions.
    Journal of the American Academy of Dermatology, 1982, Volume: 7, Issue:3

    Topics: Anti-Inflammatory Agents; Chemotaxis, Leukocyte; Humans; Immunosuppressive Agents; Leprosy; Lupus Er

1982
In vivo measurements of iron, copper and zinc in the skin of prurigo nodularis patients treated with thalidomide.
    Dermatologica, 1981, Volume: 162, Issue:2

    Topics: Adult; Copper; Female; Humans; Iron; Male; Middle Aged; Prurigo; Skin; Spectrometry, X-Ray Emission;

1981
Treatment of prurigo nodularis with thalidomide.
    Archives of dermatology, 1980, Volume: 116, Issue:5

    Topics: Humans; Male; Middle Aged; Prurigo; Thalidomide

1980
Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide.
    Journal of the American Academy of Dermatology, 1995, Volume: 33, Issue:5 Pt 1

    Topics: Acquired Immunodeficiency Syndrome; HIV Infections; Humans; Male; Middle Aged; Photosensitivity Diso

1995
Guidelines for the clinical use and dispensing of thalidomide.
    Postgraduate medical journal, 1995, Volume: 71, Issue:832

    Topics: Adolescent; Adult; Aged; Child; Clinical Protocols; Female; Humans; Male; Middle Aged; Photosensitiv

1995
Erythroderma due to thalidomide: report of two cases.
    Dermatology (Basel, Switzerland), 1994, Volume: 189, Issue:2

    Topics: Adult; Dermatitis, Exfoliative; Drug Eruptions; Eosinophilia; Female; Humans; Kidney Failure, Chroni

1994
[Thalidomide treatment of prurigo nodularis].
    Ugeskrift for laeger, 1993, Sep-20, Volume: 155, Issue:38

    Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neurodermatitis; Prurigo; Thalido

1993
Thalidomide-induced toxic pustuloderma.
    Clinical and experimental dermatology, 1997, Volume: 22, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Exfoliative; Drug Eruptions; Female; Hum

1997
[Thalidomide once more in the spotlight].
    Nederlands tijdschrift voor geneeskunde, 1999, Jan-09, Volume: 143, Issue:2

    Topics: Adult; Dermatologic Agents; Drug Approval; Female; HIV Wasting Syndrome; Humans; Immunosuppressive A

1999
Treatment of AIDS-associated prurigo nodularis with thalidomide.
    Clinical and experimental dermatology, 1998, Volume: 23, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Dermatologic Agents; Humans; Male; Prurigo; Thalidomide

1998
F-chronodispersion in patients on thalidomide.
    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 1999, Volume: 110, Issue:4

    Topics: Adolescent; Adult; Aged; Electromyography; Female; Humans; Male; Middle Aged; Muscles; Neural Conduc

1999
Thalidomide neuropathy: role of F-wave monitoring.
    Muscle & nerve, 2000, Volume: 23, Issue:8

    Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Neural Conduct

2000
Effectors of inflammation in actinic prurigo.
    Journal of the American Academy of Dermatology, 2001, Volume: 44, Issue:6

    Topics: Adolescent; Adult; Child; Female; Genetic Predisposition to Disease; Humans; Immunohistochemistry; I

2001
Long-term thalidomide for actinic prurigo.
    The Australasian journal of dermatology, 2001, Volume: 42, Issue:4

    Topics: Adult; HLA-DR4 Antigen; Humans; Immunosuppressive Agents; Male; Photosensitivity Disorders; Prurigo;

2001
Actinic prurigo (Hutchinson's summer prurigo).
    Clinical and experimental dermatology, 1977, Volume: 2, Issue:4

    Topics: Adult; Diagnosis, Differential; Female; Humans; Male; Photosensitivity Disorders; Prurigo; Seasons;

1977
[Treatment of prurigo nodularis Hyde using thalidomide].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1975, Volume: 26, Issue:4

    Topics: Eczema; Female; Humans; Middle Aged; Prurigo; Syndrome; Thalidomide

1975
Thalidomide: a restricted role.
    Lancet (London, England), 1992, May-30, Volume: 339, Issue:8805

    Topics: Female; Humans; Middle Aged; Prurigo; Sunlight; Thalidomide

1992
Cellular immune effects of thalidomide in actinic prurigo.
    International journal of dermatology, 1992, Volume: 31, Issue:8

    Topics: CD4-CD8 Ratio; Female; Humans; Male; Prurigo; Thalidomide; Ultraviolet Rays

1992
Thalidomide therapy. An open trial.
    International journal of dermatology, 1985, Volume: 24, Issue:2

    Topics: Adult; Aged; Central Nervous System Diseases; Erythema Multiforme; Female; Humans; Lichen Planus; Lu

1985
Development of polyneuropathy during thalidomide therapy.
    The British journal of dermatology, 1985, Volume: 112, Issue:4

    Topics: Action Potentials; Adult; Aged; Female; Humans; Leg; Male; Middle Aged; Neural Conduction; Neurons,

1985